Search Results

There are 17229 results for: content related to: Nilotinib, imatinib, and telomere homeostasis disruption in chronic myeloid leukemia

  1. You have full text access to this OnlineOpen article
    Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3- and 6-month time points

    European Journal of Haematology

    Volume 95, Issue 2, August 2015, Pages: 103–112, Simona Lapusan, Agnes Yong, Bipin N. Savani and Mohamad Mohty

    Version of Record online : 27 OCT 2014, DOI: 10.1111/ejh.12453

  2. You have full text access to this OnlineOpen article
    Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial

    British Journal of Haematology

    Volume 168, Issue 1, January 2015, Pages: 69–81, Tim H. Brümmendorf, Jorge E. Cortes, Cármino Antonio de Souza, Francois Guilhot, Ladan Duvillié, Dmitri Pavlov, Karïn Gogat, Athena M. Countouriotis and Carlo Gambacorti-Passerini

    Version of Record online : 8 SEP 2014, DOI: 10.1111/bjh.13108

  3. You have free access to this content
    Nilotinib versus imatinib

    Cancer

    Volume 118, Issue 20, 15 October 2012, Pages: 5181–5182, Rumiana Bakalova, Zhivko Zhelev and Lubomir Spasov

    Version of Record online : 25 APR 2012, DOI: 10.1002/cncr.27479

  4. You have free access to this content
    Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia

    European Journal of Clinical Investigation

    Volume 42, Issue 9, September 2012, Pages: 1016–1026, Francis Giles, François-Xavier Mahon, Bjorn Gjertsen, Ronan Swords, Boris Labar, Anna Turkina and Gianantonio Rosti

    Version of Record online : 1 MAY 2012, DOI: 10.1111/j.1365-2362.2012.02675.x

  5. You have free access to this content
    Chronic myeloid leukemia: Second-line drugs of choice

    American Journal of Hematology

    Volume 91, Issue 1, January 2016, Pages: 67–75, Carlo Gambacorti-Passerini, Andrea Aroldi, Nicoletta Cordani and Rocco Piazza

    Version of Record online : 23 DEC 2015, DOI: 10.1002/ajh.24247

  6. You have full text access to this OnlineOpen article
    Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

    American Journal of Hematology

    Volume 90, Issue 9, September 2015, Pages: 755–768, Carlo Gambacorti-Passerini, Hagop M. Kantarjian, Dong-Wook Kim, Hanna J. Khoury, Anna G. Turkina, Tim H. Brümmendorf, Ewa Matczak, Nathalie Bardy-Bouxin, Mark Shapiro, Kathleen Turnbull, Eric Leip and Jorge E. Cortes

    Version of Record online : 1 JUN 2015, DOI: 10.1002/ajh.24034

  7. You have full text access to this OnlineOpen article
    Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib

    American Journal of Hematology

    Volume 91, Issue 12, December 2016, Pages: 1206–1214, Jorge E. Cortes, Hanna J. Khoury, Hagop M. Kantarjian, Jeff H. Lipton, Dong-Wook Kim, Philippe Schafhausen, Ewa Matczak, Eric Leip, Kay Noonan, Tim H. Brümmendorf and Carlo Gambacorti-Passerini

    Version of Record online : 15 SEP 2016, DOI: 10.1002/ajh.24536

  8. You have free access to this content
    Chronic myeloid leukemia 2011: Successes, challenges, and strategies—Proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop

    American Journal of Hematology

    Volume 86, Issue 9, September 2011, Pages: 811–819, Tariq I. Mughal, Jerald P. Radich, Richard A. Van Etten, Alfonso Quintás-Cardama, Tomasz Skorski, Farhad Ravandi, Daniel J. DeAngelo, Carlo Gambacorti-Passerini, Giovanni Martinelli and Ayalew Tefferi

    Version of Record online : 17 AUG 2011, DOI: 10.1002/ajh.22097

  9. Peripheral blood cell telomere length measurements indicate that hematopoietic stem cell turnover is not significantly increased in whole blood and apheresis PLT donors

    Transfusion

    Volume 43, Issue 8, August 2003, Pages: 1089–1095, Stefan Scheding, Inci Ersöz, Ulrike Hartmann, Kerol Bartolvic, Stefan Balabanov, Abdulgabar Salama, Lothar Kanz and Tim H. Brümmendorf

    Version of Record online : 22 JUL 2003, DOI: 10.1046/j.1537-2995.2003.00457.x

  10. You have free access to this content
    Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome–positive acute lymphoblastic leukemia

    Cancer

    Volume 121, Issue 6, March 15, 2015, Pages: 863–871, Avichai Shimoni, Yulia Volchek, Maya Koren-Michowitz, Nira Varda-Bloom, Raz Somech, Noga Shem-Tov, Ronit Yerushalmi and Arnon Nagler

    Version of Record online : 11 NOV 2014, DOI: 10.1002/cncr.29141

  11. You have full text access to this OnlineOpen article
    Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib

    British Journal of Haematology

    Volume 172, Issue 1, January 2016, Pages: 97–110, Tim H. Brümmendorf, Jorge E. Cortes, Hanna J. Khoury, Hagop M. Kantarjian, Dong-Wook Kim, Philippe Schafhausen, Maureen G. Conlan, Mark Shapiro, Kathleen Turnbull, Eric Leip, Carlo Gambacorti-Passerini and Jeff H. Lipton

    Version of Record online : 4 NOV 2015, DOI: 10.1111/bjh.13801

  12. You have free access to this content
    Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment-free remission

    American Journal of Hematology

    Volume 90, Issue 3, March 2015, Pages: 242–249, Harry P. Erba

    Version of Record online : 30 JAN 2015, DOI: 10.1002/ajh.23902

  13. You have free access to this content
    Reply to the prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia

    Cancer

    Volume 118, Issue 20, 15 October 2012, Page: 5180, Susan O'Brien

    Version of Record online : 17 APR 2012, DOI: 10.1002/cncr.27524

  14. You have free access to this content
    Concise Review: Telomere Biology in Normal and Leukemic Hematopoietic Stem Cells

    STEM CELLS

    Volume 25, Issue 8, August 2007, Pages: 1853–1861, Mark W. Drummond, Stefan Balabanov, Tessa L. Holyoake and Tim H. Brummendorf

    Version of Record online : 17 MAY 2007, DOI: 10.1634/stemcells.2007-0057

  15. You have free access to this content
    How I treat newly diagnosed chronic myeloid leukemia in 2015

    American Journal of Hematology

    Volume 90, Issue 2, February 2015, Pages: 156–161, Carlo Gambacorti-Passerini and Rocco Piazza

    Version of Record online : 24 NOV 2014, DOI: 10.1002/ajh.23887

  16. Treatment-, Patient-, and Disease-Related Factors and the Emergence of Adverse Events with Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 33, Issue 8, August 2013, Pages: 868–881, Elizabeth Irvine and Casey Williams

    Version of Record online : 3 APR 2013, DOI: 10.1002/phar.1266

  17. You have full text access to this OnlineOpen article
    Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance

    EMBO Molecular Medicine

    Volume 5, Issue 8, August 2013, Pages: 1247–1262, Irina Lonskaya, Michaeline L. Hebron, Nicole M. Desforges, Alexander Franjie and Charbel E.-H. Moussa

    Version of Record online : 4 JUL 2013, DOI: 10.1002/emmm.201302771

  18. New insights into small-molecule inhibitors of Bcr-Abl

    Medicinal Research Reviews

    Volume 31, Issue 1, January 2011, Pages: 1–41, S. Schenone, O. Bruno, M. Radi and M. Botta

    Version of Record online : 27 AUG 2009, DOI: 10.1002/med.20175

  19. You have free access to this content
    Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

    British Journal of Haematology

    Volume 150, Issue 3, August 2010, Pages: 303–312, Fabio P. S. Santos, Hagop Kantarjian, Carmen Fava, Susan O’Brien, Guillermo Garcia-Manero, Farhad Ravandi, William Wierda, Deborah Thomas, Jianquin Shan and Jorge Cortes

    Version of Record online : 10 JUN 2010, DOI: 10.1111/j.1365-2141.2010.08245.x

    Corrected by:

    Corrigendum

    Vol. 155, Issue 3, 409, Version of Record online: 11 OCT 2011

  20. You have free access to this content
    Expanding Nilotinib Access in Clinical Trials (ENACT)

    Cancer

    Volume 118, Issue 1, 1 January 2012, Pages: 118–126, Franck E. Nicolini, Anna Turkina, Zhi-Xiang Shen, Neil Gallagher, Saengsuree Jootar, Bayard L. Powell, Carmino De Souza, Ming Zheng, Tomasz Szczudlo and Philipp le Coutre

    Version of Record online : 5 JUL 2011, DOI: 10.1002/cncr.26249